guest ::
| Home > Publications database > Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study. > print |
| Home > Publications database > Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study. > print |
| 001 | 274243 | ||
| 005 | 20240229154930.0 | ||
| 024 | 7 | _ | |a 10.1093/neuonc/noad055 |2 doi |
| 024 | 7 | _ | |a pmid:36916248 |2 pmid |
| 024 | 7 | _ | |a 1522-8517 |2 ISSN |
| 024 | 7 | _ | |a 1523-5866 |2 ISSN |
| 024 | 7 | _ | |a altmetric:143824964 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00529 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Chapman, Rebecca J |0 0000-0001-8050-8426 |b 0 |
| 245 | _ | _ | |a Optimising biomarkers for accurate ependymoma diagnosis, prognostication and stratification within International Clinical Trials: A BIOMECA study. |
| 260 | _ | _ | |a Oxford |c 2023 |b Oxford Univ. Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1698218910_28570 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #LA:B062# / 2023 Oct 3;25(10):1871-1882 |
| 520 | _ | _ | |a Accurate identification of brain tumour molecular subgroups is increasingly important. We aimed to establish the most accurate and reproducible ependymoma subgroup biomarker detection techniques, across 147 cases from International Society of Pediatric Oncology (SIOP) Ependymoma II trial participants, enrolled in the pan-European 'Biomarkers of Ependymoma in Children and Adolescents (BIOMECA)' study.Across six European BIOMECA laboratories we evaluated epigenetic profiling (DNA methylation array); immunohistochemistry (IHC) for nuclear p65-RELA, H3K27me3, and Tenascin-C; copy number analysis via FISH and MLPA (1q, CDKN2A), and MIP and DNA methylation array (genome-wide copy number evaluation); analysis of ZFTA- and YAP1-fusions by RT-PCR and sequencing, Nanostring and break-apart FISH.DNA Methylation profiling classified 65.3% (n=96/147) of cases as EPN-PFA and 15% (n=22/147) as ST-ZFTA fusion-positive. Immunohistochemical loss of H3K27me3 was a reproducible and accurate surrogate marker for EPN-PFA (sensitivity 99-100% across three centres). IHC for p65-RELA, FISH, and RNA-based analyses effectively identified ZFTA- and YAP1- fused supratentorial ependymomas. Detection of 1q gain using FISH exhibited only 57% inter-centre concordance and low sensitivity and specificity whilst MIP, MLPA and DNA methylation-based approaches demonstrated greater accuracy.We confirm, in a prospective trial cohort, that H3K27me3 immunohistochemistry is a robust EPN-PFA biomarker. Tenascin-C should be abandoned as a PFA marker. DNA methylation and MIP arrays are effective tools for copy number analysis of 1q gain, 6q and CDKN2A loss whilst FISH is inadequate. Fusion detection was successful, but rare novel fusions need more extensive technologies. Finally, we propose test sets to guide future diagnostic approaches. |
| 536 | _ | _ | |a 312 - Funktionelle und strukturelle Genomforschung (POF4-312) |0 G:(DE-HGF)POF4-312 |c POF4-312 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Ependymoma |2 Other |
| 650 | _ | 7 | |a biomarkers |2 Other |
| 650 | _ | 7 | |a brain tumours |2 Other |
| 650 | _ | 7 | |a neuro-oncology |2 Other |
| 650 | _ | 7 | |a paediatric |2 Other |
| 700 | 1 | _ | |a Ghasemi, David R |0 P:(DE-HGF)0 |b 1 |
| 700 | 1 | _ | |a Andreiuolo, Felipe |b 2 |
| 700 | 1 | _ | |a Zschernack, Valentina |b 3 |
| 700 | 1 | _ | |a Tauziede Espariat, Arnault |b 4 |
| 700 | 1 | _ | |a Buttarelli, Francesca R |b 5 |
| 700 | 1 | _ | |a Giangaspero, Felice |b 6 |
| 700 | 1 | _ | |a Grill, Jacques |0 0000-0003-4773-3001 |b 7 |
| 700 | 1 | _ | |a Haberler, Christine |0 0000-0003-1016-0545 |b 8 |
| 700 | 1 | _ | |a Paine, Simon M L |b 9 |
| 700 | 1 | _ | |a Scott, Ian |b 10 |
| 700 | 1 | _ | |a Jacques, Thomas S |b 11 |
| 700 | 1 | _ | |a Sill, Martin |b 12 |
| 700 | 1 | _ | |a Pfister, Stefan |0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |b 13 |u dkfz |
| 700 | 1 | _ | |a Kilday, John-Paul |0 0000-0002-0539-215X |b 14 |
| 700 | 1 | _ | |a Leblond, Pierre |0 0000-0002-7088-2614 |b 15 |
| 700 | 1 | _ | |a Massimino, Maura |b 16 |
| 700 | 1 | _ | |a Witt, Hendrik |0 P:(DE-He78)046fd145f1008f83f6236580727bbc0f |b 17 |
| 700 | 1 | _ | |a Modena, Piergiorgio |b 18 |
| 700 | 1 | _ | |a Varlet, Pascale |b 19 |
| 700 | 1 | _ | |a Pietsch, Torsten |b 20 |
| 700 | 1 | _ | |a Grundy, Richard G |b 21 |
| 700 | 1 | _ | |a Pajtler, Kristian |0 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |b 22 |e Last author |u dkfz |
| 700 | 1 | _ | |a Ritzmann, Timothy A |0 0000-0002-4438-6588 |b 23 |
| 700 | 1 | _ | |a Childhood, Biomarkers of Ependymoma in |b 24 |
| 700 | 1 | _ | |a Adolescence |b 25 |e Collaboration Author |
| 773 | _ | _ | |a 10.1093/neuonc/noad055 |g p. noad055 |0 PERI:(DE-600)2094060-9 |n 10 |p 1871-1882 |t Neuro-Oncology |v 25 |y 2023 |x 1522-8517 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:274243 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 13 |6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 17 |6 P:(DE-He78)046fd145f1008f83f6236580727bbc0f |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 22 |6 P:(DE-He78)a7c1bbac024fa232d9c6b78443328d9d |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-312 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Funktionelle und strukturelle Genomforschung |x 0 |
| 914 | 1 | _ | |y 2023 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-08 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-08 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-10-24 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-24 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2023-10-24 |
| 915 | _ | _ | |a IF >= 15 |0 StatID:(DE-HGF)9915 |2 StatID |b NEURO-ONCOLOGY : 2022 |d 2023-10-24 |
| 920 | 2 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)B062-20160331 |k B062 |l B062 Pädiatrische Neuroonkologie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)HD01-20160331 |k HD01 |l DKTK HD zentral |x 1 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)B062-20160331 |
| 980 | _ | _ | |a I:(DE-He78)HD01-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|